Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

Inclusion Criteria: * History of biopsy proven SJS/TENS with corneal opacity and neovascularization * Bilateral legal blindness (\<20/200 in better eye) * 18 years of age or older * Able to provide informed consent * Sufficiently healthy to undergo infliximab infusions, surgery, and a vigorous postoperative follow-up course * Able to administer eye medications or have a care giver able and willing to do same * Are considered eligible according to the following tuberculosis (TB) screening criteria: * Have no history of latent or active TB prior to screening. * Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination. * Have had no recent close contact with a person with active TB. * Within 6 weeks prior to the first administration of study agent, have a negative QuantiFERON-TB Gold test result (see Attachment A). Indeterminate results should be handled as outlined in the Screening Visit Section. A negative tuberculin skin test is considered acceptable if the QuantiFERON- TB Gold test is not acceptable in that country. * Have a chest radiograph (posterior-anterior view) taken within 3 months prior to the first administration of study agent and read by a qualified radiologist, with no evidence of current, active TB or old, inactive TB. Exclusion Criteria: * Visual acuity \>20/200 in better eye * Corneal blindness not due to effects of SJS/TENS * Hypersensitivity to infliximab or chemically related medication * Pregnant or l…